Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. Aristotle University of Thessaloniki, Thessaloniki, Greece

Survival: 15.9 months
Toxicity Grade: 5
Treatments: Chemotherapy
Drugs: Paraplatin
Country: Greece
City/State/Province: Thessaloniki
Hospital: Aristotle University of Thessaloniki
Journal: Link
Date: 7/2005

Patients: This Phase I/II study involved 68 women with advanced breast cancer. The median age was 57 years. Forty patients had metastases

Treatment: The treatment consisted of three chemotherapy agents: paclitaxel, carboplatin, and gefitinib.

Toxicity: Two patients died during the chemotherapy period. One patient died from an acute, massive pulmonary embolism after the first cycle. The second patient had been hospitalized for febrile neutropenia after the third cycle and died 3 days later from acute mesenteric thrombosis. In addition, grade 3-4 toxicities included neutropenia, anemia, diarrhea, thrombocytopenia, and peripheral neuropathy.

Results: The median overall survival was 15.9 months. Nine patients had a complete response to treatment, and thirty had a partial response. Twenty-one had stable disease. However, the authors concluded that "there is no additional benefit in adding gefitinib to this doublet chemotherapy regimen."

Support: AstraZeneca, Bristol-Myers Squibb and Aventis financially supported this study. AstraZeneca manufactures and/or markets gefitinib. Bristol-Myers Squibb manufactures and/or markets paclitaxel and carboplatin.

Correspondence: Dr G. Fountzilas

E-mail to a Friend Email Physician More Information